Bicara Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 17.54, 149.87, 509.06 ], "ebit_estimate": [ -237.9, -266.71, -272.38, -208.39, 38.8 ], "ebitda_estimate": [ -183.82, -208.97, -243, null, null ], "net_income_estimate": [ -220.43, -251.18, -256.77, -197.58, 47.66 ], "per_share_eps_estimate": [ -3.53, -3.79, -3.48, -2.46, 0.62 ], "eps_nri_estimate": [ -3.48, -3.7, -3.47, -2.51, -0.11 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 6.21, 3.76, 0.61, null, null ], "pretax_income_estimate": [ -220.32, -251.07, -255.55, -204.67, 52.65 ], "operating_cash_flow_per_share_estimate": [ -3.16, -3.45, -3.88, -3.27, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -48.16, -53.83, -156.93, null, null ], "gross_margin_estimate": [ null, null, 85, 87.13, 88.17 ], "operating_cash_flow_estimate": [ -191.87, -209.47, -235.58, -198.55, null ], "pettm_estimate": [ 0, 0, 0, 0, 46.28 ], "long_term_growth_rate_mean": -10.75, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -10.89, "future_eps_nri_estimate_growth": -10.75, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -19.65, "future_ebitda_estimate_growth": -15.81, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -22.07, "future_pretax_income_estimate_growth": -21.96, "future_book_value_per_share_estimate_growth": -54.44, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -64.68, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -24.01 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ null, null, null, null, null, null, null, null ], "ebit_estimate": [ -57.94, -60.26, -63.14, -65.11, -70.56, -73.95, -77.69, null ], "ebitda_estimate": [ -56.91, -57.47, -57.95, -57.94, null, null, null, null ], "net_income_estimate": [ -53.66, -56.22, -59.13, -63.58, -67.62, -71.18, -75.36, null ], "per_share_eps_estimate": [ -0.84, -0.87, -0.92, -0.91, -1, -0.98, -1.03, null ], "eps_nri_estimate": [ -0.83, -0.85, -0.9, -0.95, -1, -0.98, -1.02, -1.05 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -53.55, -56.51, -59.72, -63.55, -67.62, -71.15, -75.34, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": -10.75, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -10.89, "future_eps_nri_estimate_growth": -10.75, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -19.65, "future_ebitda_estimate_growth": -15.81, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -22.07, "future_pretax_income_estimate_growth": -21.96, "future_book_value_per_share_estimate_growth": -54.44, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -64.68, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -24.01 }